DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
57 hedge funds and large institutions have $22.8M invested in DMK Pharmaceuticals Corporation Common Stock in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 13 increasing their positions, 11 reducing their positions, and 12 closing their positions.
22% more capital invested
Capital invested by funds: $18.7M → $22.8M (+$4.09M)
18% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 11
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
2% less funds holding
Funds holding: 58 → 57 (-1)
45% less call options, than puts
Call options by funds: $311K | Put options by funds: $568K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
+$3.31M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.8M |
| 3 |
Barclays
London,
United Kingdom
|
+$342K |
| 4 |
Morgan Stanley
New York
|
+$295K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$277K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$254K |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$215K |
| 3 |
First Manhattan
New York
|
-$185K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$137K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$122K |
DMK Hedge Fund Activity: Q1 2019 in Review
57 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q1 2019, worth a combined $22.8M — up 22% from $18.7M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of DMK and 11 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 13 added.
The largest buyer was DekaBank Deutsche Girozentrale, opening a new position worth an estimated $3.31M. The largest seller was Oxford Asset Management, exiting entirely with an estimated $254K sold.
- 57 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q1 2019, down from 58 in Q4 2018.
- Funds reported $22.8M of DMK Pharmaceuticals Corporation Common Stock stock for Q1 2019, up 22% quarter-over-quarter.
- 11 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q1 2019 and 12 closed out, a net change of -1 holder.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q1 2019 was DekaBank Deutsche Girozentrale, an estimated $3.31M added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q1 2019 was Oxford Asset Management, an estimated $254K sold.
Based on aggregated 13F filings for Q1 2019.